Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
June 12, 2019
Publication date:
November 21, 2019
Applicant:
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors:
Merav BASSAN, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.
Type:
Application
Filed:
June 11, 2019
Publication date:
November 21, 2019
Applicant:
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors:
Michal GEVA, Aric ORBACH, Michael HAYDEN
Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.
Type:
Application
Filed:
July 17, 2019
Publication date:
November 7, 2019
Applicants:
PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Inventors:
Michael HAYDEN, Mahmoud Abdulhossein POULADI
Abstract: This invention provides an isolated compound having the structure: or a salt thereof. The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
October 3, 2018
Date of Patent:
September 10, 2019
Assignee:
PRILENIA NEUROTHERAPEUTICS LTD.
Inventors:
Malle Schmidt, Malle Päri, Marit Laos, Ants Maasalu, Kalle Kaljuste